111 related articles for article (PubMed ID: 15708525)
1. Stopping the spread of cancer.
Ewan S
Drug Discov Today; 2005 Feb; 10(3):162-3. PubMed ID: 15708525
[No Abstract] [Full Text] [Related]
2. Synthetic urokinase inhibitors as potential antitumor drugs.
Steinmetzer T
IDrugs; 2003 Feb; 6(2):138-46. PubMed ID: 12789617
[TBL] [Abstract][Full Text] [Related]
3. Topoisomerase II inhibitors.
Clapp JM; Hande KR
Cancer Chemother Biol Response Modif; 2002; 20():125-49. PubMed ID: 12703203
[No Abstract] [Full Text] [Related]
4. Histone deacetylase inhibitors in cancer therapy.
Fouladi M
Cancer Invest; 2006; 24(5):521-7. PubMed ID: 16939962
[No Abstract] [Full Text] [Related]
5. Why drinking green tea could prevent cancer.
Jankun J; Selman SH; Swiercz R; Skrzypczak-Jankun E
Nature; 1997 Jun; 387(6633):561. PubMed ID: 9177339
[No Abstract] [Full Text] [Related]
6. Thymidylate synthase inhibitors.
Ismail AS; Grem JL
Cancer Chemother Biol Response Modif; 2001; 19():1-19. PubMed ID: 11686010
[No Abstract] [Full Text] [Related]
7. Diflomotecan. Ipsen.
Osheroff N
IDrugs; 2004 Mar; 7(3):257-63. PubMed ID: 15011101
[No Abstract] [Full Text] [Related]
8. Inhibition of poly(ADP-ribose) polymerase in cancer.
Plummer ER
Curr Opin Pharmacol; 2006 Aug; 6(4):364-8. PubMed ID: 16753340
[TBL] [Abstract][Full Text] [Related]
9. Targeting urokinase-type plasminogen activator and its receptor for cancer therapy.
Nozaki S; Endo Y; Nakahara H; Yoshizawa K; Ohara T; Yamamoto E
Anticancer Drugs; 2006 Nov; 17(10):1109-17. PubMed ID: 17075310
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase inhibitors: from bench to clinic.
Paris M; Porcelloni M; Binaschi M; Fattori D
J Med Chem; 2008 Mar; 51(6):1505-29. PubMed ID: 18247554
[No Abstract] [Full Text] [Related]
11. New targets for cancer chemotherapy.
Arbuck SG; Dancey J; Pluda JM; Grochow L; Murgo AJ; Ivy P; Wright J; Blaylock B; Via LE; Sausville EA
Cancer Chemother Biol Response Modif; 2001; 19():237-88. PubMed ID: 11686017
[No Abstract] [Full Text] [Related]
12. Deal watch: Bristol-Myers Squibb and Exelixis collaborate on kinase inhibitors.
Nat Rev Drug Discov; 2009 Feb; 8(2):98. PubMed ID: 19180098
[No Abstract] [Full Text] [Related]
13. CDK inhibitors in cancer therapy: what is next?
Malumbres M; Pevarello P; Barbacid M; Bischoff JR
Trends Pharmacol Sci; 2008 Jan; 29(1):16-21. PubMed ID: 18054800
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase inhibitors: overview and perspectives.
Dokmanovic M; Clarke C; Marks PA
Mol Cancer Res; 2007 Oct; 5(10):981-9. PubMed ID: 17951399
[TBL] [Abstract][Full Text] [Related]
15. Thymidylate synthase inhibitors.
Ackland SP; Clarke SJ; Beale P; Peters GJ
Cancer Chemother Biol Response Modif; 2002; 20():1-36. PubMed ID: 12703198
[No Abstract] [Full Text] [Related]
16. Targeting uPA/uPAR in prostate cancer.
Li Y; Cozzi PJ
Cancer Treat Rev; 2007 Oct; 33(6):521-7. PubMed ID: 17658220
[TBL] [Abstract][Full Text] [Related]
17. B-Raf kinase inhibitors for cancer treatment.
Li N; Batt D; Warmuth M
Curr Opin Investig Drugs; 2007 Jun; 8(6):452-6. PubMed ID: 17621874
[TBL] [Abstract][Full Text] [Related]
18. The crystal structures of 3-TAPAP in complexes with the urokinase-type plasminogen activator and picrate.
Zesławska E; Jacob U; Stürzebecher J; Oleksyn BJ
Bioorg Med Chem Lett; 2006 Jan; 16(1):228-34. PubMed ID: 16202591
[TBL] [Abstract][Full Text] [Related]
19. Development of farnesyltransferase inhibitors for clinical cancer therapy: focus on hematologic malignancies.
Karp JE; Lancet JE
Cancer Invest; 2007 Sep; 25(6):484-94. PubMed ID: 17882662
[TBL] [Abstract][Full Text] [Related]
20. Small, potent, and selective diaryl phosphonate inhibitors for urokinase-type plasminogen activator with in vivo antimetastatic properties.
Joossens J; Ali OM; El-Sayed I; Surpateanu G; Van der Veken P; Lambeir AM; Setyono-Han B; Foekens JA; Schneider A; Schmalix W; Haemers A; Augustyns K
J Med Chem; 2007 Dec; 50(26):6638-46. PubMed ID: 18052026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]